Drug Trial Radar · NCT00092963
Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)
Last checked: Nov 19, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
529
Actual
Start
Aug 17, 2004
Primary completion
Jan 14, 2005
Study completion Jan 14, 2005
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Sep 29, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine while the pain is still mild.
Conditions
- Migraine
Interventions
MK0462, rizatriptan benzoate / Duration of Treatment: 1dayDrug
Comparator: placebo / Duration of Treatment: 1 dayDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients who are pain free at 2 hours postdose.
- Tolerability as measured by subjective adverse experience reporting.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.